Loading…

Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)

Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Sea...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2023, Vol.161 (2), p.415-423
Main Authors: Pei, Jian, Li, Pei, Gao, Yun H., Tian, Bao G., Wang, Da Y., Zheng, Yu, Liu, Li Y., Zhang, Zhi Y., Huang, Si S., Wen, Min, Xu, Xiang, Xia, Lei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43
cites cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43
container_end_page 423
container_issue 2
container_start_page 415
container_title Journal of neuro-oncology
container_volume 161
creator Pei, Jian
Li, Pei
Gao, Yun H.
Tian, Bao G.
Wang, Da Y.
Zheng, Yu
Liu, Li Y.
Zhang, Zhi Y.
Huang, Si S.
Wen, Min
Xu, Xiang
Xia, Lei
description Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. Methods We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. Results A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass ( p  = 0.0132) than the brain-invasive group, which showed moderate intensity. Conclusion This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.
doi_str_mv 10.1007/s11060-023-04256-z
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9988792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2783523105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</originalsourceid><addsrcrecordid>eNp9kstuEzEUhi0EoqHwAiyQJTZlYWqPbzMskFDEpVIqFi2IneWxnYmriT21ZwLpinfgDXg0ngSnKeWyYGXp_N_5fY79A_CY4OcEY3mcCcECI1xRhFnFBbq6A2aES4oklfQumGEiJOIN-3QAHuR8gTFmkpL74ICKmhAp-Ax8P98ODp58hCb2ve5cQNYlv3EW6tD5WAou-wx9WPnWjzG9gEaHPOrRB9jHz9B9GZLL2YeuMLBN2gfkw0bn4gHXLvidy1pnOF0zvb-cvIVmlUpxjF3Sw2r74-u3QmSYB2fGIrgxbeHRYo5Oz45Pz549BPeWus_u0c15CD68eX0-f4cW79-ezF8tkGGSjcji2hAirOac1aJxjag5pnbJGsOlaLXhvKkqS7AxumVL3RomBK-01TUmtWX0ELzc-w5Tu3bWuDAm3ash-bVOWxW1V38rwa9UFzeqaepaNlUxOLoxSPFycnlUa5-NK-8aXJyyqqRsKMeM7tCn_6AXcUqhrFeomvKKEswLVe0pk2LOyS1vhyFY7SKg9hFQJQLqOgLqqjQ9-XON25Zff14AugdykULn0u-7_2P7E9_8wos</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2783523105</pqid></control><display><type>article</type><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><source>Springer Nature</source><creator>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</creator><creatorcontrib>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</creatorcontrib><description>Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. Methods We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. Results A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass ( p  = 0.0132) than the brain-invasive group, which showed moderate intensity. Conclusion This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-023-04256-z</identifier><identifier>PMID: 36811765</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiogenesis Inhibitors ; Brain - pathology ; Brain cancer ; Chromatography ; Chromatography, Liquid ; Collagen (type IV) ; Collagen Type IV - metabolism ; Diagnosis ; Glial fibrillary acidic protein ; Humans ; Liquid chromatography ; Mass spectrometry ; Mass spectroscopy ; Medical innovations ; Medicine ; Medicine &amp; Public Health ; Meningeal Neoplasms - pathology ; Meningioma - pathology ; Neurology ; Oncology ; Proteins ; Proteomics ; Scientific imaging ; Tandem Mass Spectrometry ; Therapeutic targets</subject><ispartof>Journal of neuro-oncology, 2023, Vol.161 (2), p.415-423</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</citedby><cites>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</cites><orcidid>0000-0002-7439-7683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36811765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pei, Jian</creatorcontrib><creatorcontrib>Li, Pei</creatorcontrib><creatorcontrib>Gao, Yun H.</creatorcontrib><creatorcontrib>Tian, Bao G.</creatorcontrib><creatorcontrib>Wang, Da Y.</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Liu, Li Y.</creatorcontrib><creatorcontrib>Zhang, Zhi Y.</creatorcontrib><creatorcontrib>Huang, Si S.</creatorcontrib><creatorcontrib>Wen, Min</creatorcontrib><creatorcontrib>Xu, Xiang</creatorcontrib><creatorcontrib>Xia, Lei</creatorcontrib><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. Methods We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. Results A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass ( p  = 0.0132) than the brain-invasive group, which showed moderate intensity. Conclusion This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</description><subject>Angiogenesis Inhibitors</subject><subject>Brain - pathology</subject><subject>Brain cancer</subject><subject>Chromatography</subject><subject>Chromatography, Liquid</subject><subject>Collagen (type IV)</subject><subject>Collagen Type IV - metabolism</subject><subject>Diagnosis</subject><subject>Glial fibrillary acidic protein</subject><subject>Humans</subject><subject>Liquid chromatography</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medical innovations</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningioma - pathology</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Scientific imaging</subject><subject>Tandem Mass Spectrometry</subject><subject>Therapeutic targets</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kstuEzEUhi0EoqHwAiyQJTZlYWqPbzMskFDEpVIqFi2IneWxnYmriT21ZwLpinfgDXg0ngSnKeWyYGXp_N_5fY79A_CY4OcEY3mcCcECI1xRhFnFBbq6A2aES4oklfQumGEiJOIN-3QAHuR8gTFmkpL74ICKmhAp-Ax8P98ODp58hCb2ve5cQNYlv3EW6tD5WAou-wx9WPnWjzG9gEaHPOrRB9jHz9B9GZLL2YeuMLBN2gfkw0bn4gHXLvidy1pnOF0zvb-cvIVmlUpxjF3Sw2r74-u3QmSYB2fGIrgxbeHRYo5Oz45Pz549BPeWus_u0c15CD68eX0-f4cW79-ezF8tkGGSjcji2hAirOac1aJxjag5pnbJGsOlaLXhvKkqS7AxumVL3RomBK-01TUmtWX0ELzc-w5Tu3bWuDAm3ash-bVOWxW1V38rwa9UFzeqaepaNlUxOLoxSPFycnlUa5-NK-8aXJyyqqRsKMeM7tCn_6AXcUqhrFeomvKKEswLVe0pk2LOyS1vhyFY7SKg9hFQJQLqOgLqqjQ9-XON25Zff14AugdykULn0u-7_2P7E9_8wos</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Pei, Jian</creator><creator>Li, Pei</creator><creator>Gao, Yun H.</creator><creator>Tian, Bao G.</creator><creator>Wang, Da Y.</creator><creator>Zheng, Yu</creator><creator>Liu, Li Y.</creator><creator>Zhang, Zhi Y.</creator><creator>Huang, Si S.</creator><creator>Wen, Min</creator><creator>Xu, Xiang</creator><creator>Xia, Lei</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7439-7683</orcidid></search><sort><creationdate>2023</creationdate><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><author>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis Inhibitors</topic><topic>Brain - pathology</topic><topic>Brain cancer</topic><topic>Chromatography</topic><topic>Chromatography, Liquid</topic><topic>Collagen (type IV)</topic><topic>Collagen Type IV - metabolism</topic><topic>Diagnosis</topic><topic>Glial fibrillary acidic protein</topic><topic>Humans</topic><topic>Liquid chromatography</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medical innovations</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningioma - pathology</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Scientific imaging</topic><topic>Tandem Mass Spectrometry</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pei, Jian</creatorcontrib><creatorcontrib>Li, Pei</creatorcontrib><creatorcontrib>Gao, Yun H.</creatorcontrib><creatorcontrib>Tian, Bao G.</creatorcontrib><creatorcontrib>Wang, Da Y.</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Liu, Li Y.</creatorcontrib><creatorcontrib>Zhang, Zhi Y.</creatorcontrib><creatorcontrib>Huang, Si S.</creatorcontrib><creatorcontrib>Wen, Min</creatorcontrib><creatorcontrib>Xu, Xiang</creatorcontrib><creatorcontrib>Xia, Lei</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pei, Jian</au><au>Li, Pei</au><au>Gao, Yun H.</au><au>Tian, Bao G.</au><au>Wang, Da Y.</au><au>Zheng, Yu</au><au>Liu, Li Y.</au><au>Zhang, Zhi Y.</au><au>Huang, Si S.</au><au>Wen, Min</au><au>Xu, Xiang</au><au>Xia, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2023</date><risdate>2023</risdate><volume>161</volume><issue>2</issue><spage>415</spage><epage>423</epage><pages>415-423</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. Methods We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. Results A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass ( p  = 0.0132) than the brain-invasive group, which showed moderate intensity. Conclusion This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36811765</pmid><doi>10.1007/s11060-023-04256-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7439-7683</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-594X
ispartof Journal of neuro-oncology, 2023, Vol.161 (2), p.415-423
issn 0167-594X
1573-7373
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9988792
source Springer Nature
subjects Angiogenesis Inhibitors
Brain - pathology
Brain cancer
Chromatography
Chromatography, Liquid
Collagen (type IV)
Collagen Type IV - metabolism
Diagnosis
Glial fibrillary acidic protein
Humans
Liquid chromatography
Mass spectrometry
Mass spectroscopy
Medical innovations
Medicine
Medicine & Public Health
Meningeal Neoplasms - pathology
Meningioma - pathology
Neurology
Oncology
Proteins
Proteomics
Scientific imaging
Tandem Mass Spectrometry
Therapeutic targets
title Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A37%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%20IV%20collagen-derived%20angiogenesis%20inhibitor:%20canstatin%20low%20expressing%20in%20brain-invasive%20meningiomas%20using%20liquid%20chromatography%E2%80%93mass%20spectrometry%20(LC-MS/MS)&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Pei,%20Jian&rft.date=2023&rft.volume=161&rft.issue=2&rft.spage=415&rft.epage=423&rft.pages=415-423&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-023-04256-z&rft_dat=%3Cproquest_pubme%3E2783523105%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2783523105&rft_id=info:pmid/36811765&rfr_iscdi=true